Cargando…

In silico study of fragile histidine triad interaction domains with MDM2 and p53

BACKGROUND: Fragile histidine triad (FHIT) is considered as a member of the histidine triad (HIT) nucleotide-binding protein superfamily regarded as a putative tumor suppressor executing crucial role in inhibiting p53 degradation by MDM2. Accumulating evidences indicate FHIT interaction with p53 or...

Descripción completa

Detalles Bibliográficos
Autores principales: Eslamparast, Ameneh, Ghahremani, Mohammad Hossein, Sardari, Soroush
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4162077/
https://www.ncbi.nlm.nih.gov/pubmed/25221773
http://dx.doi.org/10.4103/2277-9175.139178
_version_ 1782334646918316032
author Eslamparast, Ameneh
Ghahremani, Mohammad Hossein
Sardari, Soroush
author_facet Eslamparast, Ameneh
Ghahremani, Mohammad Hossein
Sardari, Soroush
author_sort Eslamparast, Ameneh
collection PubMed
description BACKGROUND: Fragile histidine triad (FHIT) is considered as a member of the histidine triad (HIT) nucleotide-binding protein superfamily regarded as a putative tumor suppressor executing crucial role in inhibiting p53 degradation by MDM2. Accumulating evidences indicate FHIT interaction with p53 or MDM2; however, there is no certain study deciphering functional domains of FHIT involving in the interaction with MDM2 and/or p53. In this regard, such evident interaction can spring in mind determining important domains of FHIT binding to MDM2 with regard to p53. MATERIALS AND METHODS: Since there were not any previous studies appraising complete three-dimensional structures of target molecules, molecular modeling was carried out to construct three-dimensional models of full FHIT, MDM2, P53 and also FHIT segments. Truncated structures of FHIT were created to reveal critical regions engaging in FHIT interaction. RESULTS: Given the shape and shape/electrostatic total energy, FHIT structures (β1-5), (β3-7, α1), and (β5-7, α1) appeared to be better candidates than other structures in interaction with full MDM2. Furthermore, FHIT structures (β6-7), (β6-7, α1), (β4-7, α1) were considered to be better than other structures in interaction with p53. FHIT truncates that interact with MDM2 presented lower energy levels than FHIT truncates interacting with p53. CONCLUSION: These findings are beneficial to understand the mechanism of the FHIT-MDM2-p53 complex activation for designing inhibitory compounds.
format Online
Article
Text
id pubmed-4162077
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-41620772014-09-14 In silico study of fragile histidine triad interaction domains with MDM2 and p53 Eslamparast, Ameneh Ghahremani, Mohammad Hossein Sardari, Soroush Adv Biomed Res Original Article BACKGROUND: Fragile histidine triad (FHIT) is considered as a member of the histidine triad (HIT) nucleotide-binding protein superfamily regarded as a putative tumor suppressor executing crucial role in inhibiting p53 degradation by MDM2. Accumulating evidences indicate FHIT interaction with p53 or MDM2; however, there is no certain study deciphering functional domains of FHIT involving in the interaction with MDM2 and/or p53. In this regard, such evident interaction can spring in mind determining important domains of FHIT binding to MDM2 with regard to p53. MATERIALS AND METHODS: Since there were not any previous studies appraising complete three-dimensional structures of target molecules, molecular modeling was carried out to construct three-dimensional models of full FHIT, MDM2, P53 and also FHIT segments. Truncated structures of FHIT were created to reveal critical regions engaging in FHIT interaction. RESULTS: Given the shape and shape/electrostatic total energy, FHIT structures (β1-5), (β3-7, α1), and (β5-7, α1) appeared to be better candidates than other structures in interaction with full MDM2. Furthermore, FHIT structures (β6-7), (β6-7, α1), (β4-7, α1) were considered to be better than other structures in interaction with p53. FHIT truncates that interact with MDM2 presented lower energy levels than FHIT truncates interacting with p53. CONCLUSION: These findings are beneficial to understand the mechanism of the FHIT-MDM2-p53 complex activation for designing inhibitory compounds. Medknow Publications & Media Pvt Ltd 2014-08-19 /pmc/articles/PMC4162077/ /pubmed/25221773 http://dx.doi.org/10.4103/2277-9175.139178 Text en Copyright: © 2014 Eslamparast. http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Original Article
Eslamparast, Ameneh
Ghahremani, Mohammad Hossein
Sardari, Soroush
In silico study of fragile histidine triad interaction domains with MDM2 and p53
title In silico study of fragile histidine triad interaction domains with MDM2 and p53
title_full In silico study of fragile histidine triad interaction domains with MDM2 and p53
title_fullStr In silico study of fragile histidine triad interaction domains with MDM2 and p53
title_full_unstemmed In silico study of fragile histidine triad interaction domains with MDM2 and p53
title_short In silico study of fragile histidine triad interaction domains with MDM2 and p53
title_sort in silico study of fragile histidine triad interaction domains with mdm2 and p53
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4162077/
https://www.ncbi.nlm.nih.gov/pubmed/25221773
http://dx.doi.org/10.4103/2277-9175.139178
work_keys_str_mv AT eslamparastameneh insilicostudyoffragilehistidinetriadinteractiondomainswithmdm2andp53
AT ghahremanimohammadhossein insilicostudyoffragilehistidinetriadinteractiondomainswithmdm2andp53
AT sardarisoroush insilicostudyoffragilehistidinetriadinteractiondomainswithmdm2andp53